FDA Accepts LEQEMBI ® (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer's Disease
China's National Medical Products Administration (NMPA) Approves PADCEV™ in combination with KEYTRUDA ® (pembrolizumab) for the Treatment of Advanced Bladder Cancer
ACM Research's proprietary technologies offer superior cleaning efficiency, positioning it well in the booming semiconductor industry. See why ACMR stock is a Buy.